Electrocardiographic characterization of ramucirumab on the corrected qt interval in a phase ii study of patients with advanced solid tumors
- Anthony J. Olszanski
- , David C. Smith
- , Luis H. Camacho
- , John Thompson
- , Suresh S. Ramalingam
- , R. Donald Harvey
- , Luis Campos
- , David Ferry
- , Shande Tang
- , Ling Gao
- , Howard Safran
- University of Michigan, Ann Arbor
- Center for Oncology and Blood Disorders
- Seattle Cancer Care Alliance
- Emory University
- Oncology Consultants
- Eli Lilly and Company
- Rhode Island Hospital
Research output: Contribution to journal › Article › peer-review
2
Scopus
citations